vs
Side-by-side financial comparison of Global-E Online Ltd. (GLBE) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Global-E Online Ltd. is the larger business by last-quarter revenue ($625.5M vs $619.8M, roughly 1.0× QuidelOrtho Corp). Global-E Online Ltd. runs the higher net margin — 0.9% vs -14.8%, a 15.7% gap on every dollar of revenue.
Global-E Online Ltd. operates a leading cross-border e-commerce enablement platform that helps direct-to-consumer brands and retail enterprises expand their international sales reach. It offers end-to-end services including localized checkout, payment processing, customs clearance, logistics coordination, and duty calculation, serving clients across North America, Europe, and the Asia-Pacific region.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
GLBE vs QDEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $625.5M | $619.8M |
| Net Profit | $5.8M | $-91.8M |
| Gross Margin | 45.0% | — |
| Operating Margin | 1.3% | — |
| Net Margin | 0.9% | -14.8% |
| Revenue YoY | — | -10.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q3 25 | $625.5M | $699.9M | ||
| Q2 25 | $404.8M | $613.9M | ||
| Q1 25 | $189.9M | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | $489.9M | $727.1M | ||
| Q2 24 | $313.9M | $637.0M | ||
| Q1 24 | $145.9M | $711.0M |
| Q1 26 | — | $-91.8M | ||
| Q3 25 | $5.8M | $-733.0M | ||
| Q2 25 | $-7.4M | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-77.1M | $-19.9M | ||
| Q2 24 | $-54.5M | $-147.7M | ||
| Q1 24 | — | $-1.7B |
| Q1 26 | — | — | ||
| Q3 25 | 45.0% | — | ||
| Q2 25 | 44.9% | — | ||
| Q1 25 | 44.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 45.1% | — | ||
| Q2 24 | 44.8% | — | ||
| Q1 24 | 43.4% | — |
| Q1 26 | — | — | ||
| Q3 25 | 1.3% | -100.7% | ||
| Q2 25 | -2.1% | -29.4% | ||
| Q1 25 | -10.1% | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | -14.9% | 2.1% | ||
| Q2 24 | -16.6% | -18.4% | ||
| Q1 24 | -20.1% | -247.3% |
| Q1 26 | — | -14.8% | ||
| Q3 25 | 0.9% | -104.7% | ||
| Q2 25 | -1.8% | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -15.7% | -2.7% | ||
| Q2 24 | -17.4% | -23.2% | ||
| Q1 24 | — | -239.9% |
| Q1 26 | — | $-1.35 | ||
| Q3 25 | — | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $-2.20 | ||
| Q1 24 | — | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $251.4M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $933.0M | $1.9B |
| Total Assets | $1.3B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q3 25 | $251.4M | $98.1M | ||
| Q2 25 | $205.2M | $151.7M | ||
| Q1 25 | $207.7M | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | $207.3M | $143.7M | ||
| Q2 24 | $229.8M | $107.0M | ||
| Q1 24 | $181.9M | $78.5M |
| Q1 26 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q3 25 | $933.0M | $2.0B | ||
| Q2 25 | $909.1M | $2.8B | ||
| Q1 25 | $884.3M | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | $869.4M | $3.2B | ||
| Q2 24 | $878.7M | $3.2B | ||
| Q1 24 | $886.9M | $3.3B |
| Q1 26 | — | $5.6B | ||
| Q3 25 | $1.3B | $5.7B | ||
| Q2 25 | $1.2B | $6.4B | ||
| Q1 25 | $1.2B | $6.5B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | $1.2B | $6.8B | ||
| Q2 24 | $1.1B | $6.7B | ||
| Q1 24 | $1.1B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLBE
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
